TECKRO
9.11.2021 15:06:09 CET | Business Wire | Press release
Teckro, creator of the only clinical trial platform that facilitates collaboration between and among stakeholders, today announced the launch of the Totally Clinical: Trial Triumphs & Rad Trends podcast. The series provides a medium for diverse stakeholders in the clinical trial ecosystem to engage in conversation; inspiring new ways to design, deliver, and improve participation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005899/en/
To promote the new podcast series, Teckro worked with award-winning actor John C. McGinley. Known as Dr. Perry Cox in the hit television series Scrubs , McGinley stars in a video introducing Totally Clinical .
Totally Clinical episodes cover a variety of topics, ranging from field research perspectives and patient experiences, to drug development advances and technology trends. Gary Hughes, Teckro co-founder and CEO, kicks off the series by talking about operating for the greater good and what it means to be a mission-driven company in the 21st Century.
“Teckro is already the hub for effective communication; connecting stakeholders despite the complex, distributed, and often siloed nature of clinical trials,” says Hughes. “Now with the introduction of the Totally Clinical podcast, we are broadening our ambition to engage even more stakeholders in conversations; advancing clinical research and expanding awareness of clinical trials as an option for best possible care.”
Other topics include:
- Dr. Deborah Zajchowski, scientific director for the non-profit Clearity Foundation , discusses how targeted clinical trials based on tumor biomarkers can help increase survival rates for ovarian cancer.
- Dr. Brendan Buckley, Teckro Chief Medical Officer, explores trends in clinical trials –from mega trials to personalized medicine.
- Lydia Beaudette, manager of growth at LMC Manna Research , presents the research site viewpoint and ways to reduce the burden of technology on staff who are already stretched thin.
- Maria Milas takes us through the “day in the life” of a clinical research associate (CRA) and how the pandemic is driving change for the better.
- And Martin Lovell, a prostate cancer survivor, recounts how a chance reading of a newspaper article saved his life.
“Every initiative that gets people talking is a step forward,” says Dr. Zajchowski, “but the Totally Clinical podcast series is also a chance for non-profit organizations to reach other audiences. It allows us to engage in conversations that might accelerate research for treatments and drugs that improve outcomes and survival.”
The Totally Clinical: Trial Triumphs & Rad Trends podcast is available ad-free on Spotify , Apple , and Google . If you are interested in submitting a topic for consideration, contact us .
About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials. Teckro works with emerging biotech and global pharmaceutical organizations, including 12 out of the Top 20 companies. Teckro supports all therapeutic areas, all phases, and any trial format including traditional in-clinic, decentralized clinical trials, or a hybrid approach.
More Information
- Visit teckro.com
- Connect with Teckro on LinkedIn
- Follow @teckroofficial on Twitter and Instagram
- Like Teckro on Facebook
- Subscribe to the Teckro YouTube channel
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005899/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG’s MidOcean Energy Announces Initial Equity Raise of $1.2 billion Versus $1.0 billion Cover17.3.2026 08:26:00 CET | Press release
MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced an equity capital raise of more than $1.2 billion. This equity raise includes: a $500 million commitment from Idemitsu Kosan, a highly respected global energy company with a long-standing presence across the energy value chain; and additional commitments of $790 million from both new and existing investors. This represents a significant milestone in MidOcean’s capital formation program and reflects continued interest from both new and existing investors in the Company’s strategy to seek to build a diversified, resilient, long-life global LNG platform. There is significant further momentum from additional investors currently in documentation. MidOcean will continue to raise capital, with a cumulative target of up to $2 billion from new investors. The Company has received substantial interest from investors seeking long-term exposure to the LNG sector, supported
RS2 Launches “Beyond by RS2” to Power the Next Generation of European Fintech17.3.2026 08:00:00 CET | Press release
RS2, a Tier-1 global provider of payment processing infrastructure and technology solutions, today announced the launch of Beyond by RS2, a new digital payments brand designed to help fintech companies, platforms, and payment providers rapidly launch card issuing and payment acceptance services across Europe. Built on RS2’s globally proven BankWORKS platform, Beyond by RS2 offers fintechs a comprehensive sponsored issuer and acquiring program, enabling partners to issue cards and process payments without needing their own banking license or direct card scheme membership. The program leverages RS2’s Electronic Money Institution (EMI) license in Germany and its principal membership with Visa and Mastercard, allowing fintech partners to operate under RS2’s regulated infrastructure while maintaining their own customer experience and brand. “Beyond by RS2 represents a major step in our strategy to enable innovation in payments,” said Radi El Haj, CEO, RS2. “Fintechs today want to build powe
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom